Updated notice to holders of ADSs regarding termination of Deposit Agreement
2022年8月9日 - 5:30AM
NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES
(“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS
(“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES OF:ZEALAND PHARMA
A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 98920Y304 AND
UNDERLYING ISIN: DK0060257814
Company announcement – No. 33 / 2022
Copenhagen, DK and Boston,
MA, August 8,
2022 – Zealand Pharma A/S (“Zealand” or
the “Company”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a
Copenhagen-headquartered biotechnology company focused on the
discovery and development of innovative peptide-based medicines,
hereby provides notice to holders of American Depositary Shares
(“ADSs”) evidenced by American Depositary Receipts (“ADRs”)
representing deposited ordinary shares of the Company regarding
termination of the Deposit Agreement (the “Deposit Agreement”),
dated August 8, 2017, among the Company, The Bank of New York
Mellon, as depositary (the “the Depositary”), and Owners and ADR
Holders (“ADR Holders”).
On August 3, 2022, ADR Holders were notified by the Depositary
that the Depositary will terminate the Deposit Agreement effective
at 5:00 PM (Eastern Time) on November 2, 2022.
Under the terms of the Deposit Agreement, ADR Holders have until
at least November 7, 2022, to surrender their Zealand ADRs for
delivery of the underlying shares. If ADR Holders surrender ADRs
for delivery of the underlying shares, ADR Holders must pay a cable
fee of $17.50, a cancellation fee of up to $0.05 per ADR
surrendered and any applicable U.S. or local taxes or governmental
charges. Payment should be made payable to the Depositary.
Subsequent to November 7, 2022, under the terms of the Deposit
Agreement, the Depositary may attempt to sell the underlying
shares. If the Depositary has sold such shares, ADR Holders must
surrender their ADRs to obtain payment of the sale proceeds, net of
the expenses of sale, any applicable U.S. or local taxes or
government charges and a cancellation fee of up to $0.05 per
ADR.
In order to convert ADSs to ordinary shares of the Company, ADR
Holders should instruct their brokers to surrender ADSs to The Bank
of New York Mellon (DTC No. 2504). In connection with this
surrender, brokers should include ongoing common share delivery
instructions in the comments field within DTC, including
information such as the name and BIC of the appropriate local
bank/broker and/or appropriate delivery code, beneficiary name and
account number. U.S. brokers holding ADSs on behalf of their
clients, can reach out to DRSettlements@BNYMellon.com for questions
regarding the conversion and settlement process.
# # #
About Zealand Pharma A/SZealand Pharma A/S
(Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on
the discovery and development of peptide-based medicines. More than
10 drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. In addition, license
collaborations with Boehringer Ingelheim and AstraZeneca create
opportunities for more patients to potentially benefit from
Zealand-invented peptide investigational agents currently in
development.Zealand was founded in 1998 and is headquartered in
Copenhagen, Denmark, with a presence in the U.S. that includes
Boston. For more information about Zealand’s business and
activities, please visit www.zealandpharma.com.
Forward-Looking StatementThe above information
contains forward-looking statements that provide Zealand Pharma’s
expectations or forecasts of future events, including
forward-looking statements about the termination of the Company’s
ADR program. Such forward-looking statements are subject to risks,
uncertainties and inaccurate assumptions, which may cause actual
results to differ materially from expectations set forth herein and
may cause any or all of such forward-looking statements to be
incorrect. If any or all of such forward-looking statements prove
to be incorrect, our actual results could differ materially and
adversely from those anticipated or implied by such statements. All
such forward-looking statements speak only as of the date of this
release and are based on information available to Zealand Pharma as
of the date of this release. Except as required by law, the Company
assumes no obligation to update these forward-looking statements
publicly.
Contact:
Anna Krassowska, PhDVice President, Investor Relations &
Corporate CommunicationsZealand PharmaEmail:
ank@zealandpharma.com
David Rosen (U.S. Media)Argot PartnersEmail:
media@zealandpharma.com
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 5 2024 まで 6 2024
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 6 2023 まで 6 2024